{"disease":{"id":"diphtheria","name":"Diphtheria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"penicillin-g-sodium","indication_name":"Diphtheria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"benzylpenicillin","indication_name":"Diphtheria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"erythromycin","indication_name":"Diphtheria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"E-Mycin","generic_name":"erythromycin","company_name":"Generic (originally Abbott/Lilly)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1","drug_class":"Macrolide [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"dtacp-ipv-combined-vaccine-tetraxim","indication_name":"Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DTacP-IPV combined vaccine (TETRAXIM™)","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3","drug_class":"Combination inactivated vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adult)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (immunocompromised)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (pregnancy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hospital-based-vaccination-pathway","indication_name":"Tetanus, diphtheria, and pertussis (Tdap) booster (adolescent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hospital-Based Vaccination Pathway","generic_name":"hospital-based-vaccination-pathway","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various pathogens","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"menacwy-vaccine","indication_name":"Tetanus, diphtheria, and pertussis toxoids adsorbed (Tdap) booster dose in individuals 11 through 64 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MenACWY Vaccine","generic_name":"menacwy-vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Meningococcal antigens","drug_class":"Conjugate vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age, when used in a 3-dose series.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"infanrix","indication_name":"Prevention of diphtheria, tetanus, and pertussis in infants and children aged 6 weeks through 6 years","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infanrix","generic_name":"infanrix","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"vaccine","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"erythrocin","indication_name":"Diphtheria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"Erythromycin Lactobionate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"penicillin","indication_name":"Diphtheria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03950986","title":"Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System","phase":"NA","overall_status":"COMPLETED","enrollment_count":67000,"lead_sponsor_name":"Atlanta VA Medical Center","has_results":false},{"nct_id":"NCT07444502","title":"Safety Monitoring of Boostagen® Vaccine in Thailand","phase":"","overall_status":"COMPLETED","enrollment_count":10727,"lead_sponsor_name":"BioNet-Asia Co., Ltd.","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT00148941","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4209,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04056728","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT04061382","title":"Sero-epidemiological Survey of England in 2019/2020 - COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":2963,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05091619","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2898,"lead_sponsor_name":"China National Biotec Group Company Limited","has_results":false},{"nct_id":"NCT00325156","title":"Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2590,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05951725","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2520,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT02757950","title":"A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.","phase":"","overall_status":"COMPLETED","enrollment_count":2462,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00346073","title":"Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2337,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04177485","title":"Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":1962,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT00489970","title":"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1954,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06708286","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1820,"lead_sponsor_name":"CanSino Biologics Inc.","has_results":false},{"nct_id":"NCT00385255","title":"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1726,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04424693","title":"Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Institute of Arthritis Research","has_results":false},{"nct_id":"NCT05457946","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":1438,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT00463437","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1437,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02587520","title":"Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1363,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT00282295","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1344,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00835237","title":"Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1332,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00908115","title":"Post Market Surveillance for Infanrix™","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01086423","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":985,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00432042","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":955,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04398706","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":852,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT01449812","title":"Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":831,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00228917","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":798,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00169442","title":"Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":745,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01248884","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00325143","title":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02377349","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":688,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01929291","title":"Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":682,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01362322","title":"Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00412854","title":"Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07418372","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":660,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT01453998","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":657,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01568060","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT00136604","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":617,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02422264","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02096263","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02853929","title":"Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":551,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00317135","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04535037","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00317187","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT00352963","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01090453","title":"Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00871117","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02458183","title":"Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":476,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT00696423","title":"Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":467,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03552445","title":"Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":462,"lead_sponsor_name":"Korea University Guro Hospital","has_results":false}],"total":50},"guidelines":[{"drug_id":"erythrocin","guideline_body":"FDA label","recommendation":"Erythrocin Lactobionate-IV is indicated as an adjunct to antitoxin for the treatment of infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.","line_of_therapy":"adj","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}